Untitled Document

Prostate Cancer Treatments at UCLA

"Prostate cancer is the most common cancer diagnosis in American men, with approximately 220,000 new cases expected in the United States this year. Advances in screening combined with aggressive treatment have led to a 25% decrease in prostate cancer related death, with a decline from more than 40,000 deaths in the early 1990s to ~30,000 deaths in 2004. UCLA Urology's Prostate Cancer Program is recognized internationally as one of the premier prostate programs in the world both for its cutting edge research and clinical programs. UCLA is one of only 11 centers nationwide recognized as a Center of Excellence in prostate cancer and is funded by an $11 million "SPORE" grant from the National Cancer Institute for prostate cancer research.

UCLA's Prostate Cancer Program is committed to providing the full spectrum of cancer care for its patients, based on the belief that no single treatment is right for every individual. For early stage prostate cancer, we offer nerve-sparing radical prostatectomy, robotically assisted laparoscopic prostatectomy, permanent and temporary brachytherapy, cryotherapy and external beam radiotherapy (IMRT). Uniquely, patient care at UCLA is integrated closely with our research mission in order to advance the state of the art. Examples of this include the integration of quality of life assessments with treatment for early stage disease and the availability of clinical trials stemming from UCLA research and beyond for men with locally advanced and metastatic cancers.

Robotically-assisted laparoscopic prostatectomy is one of the newest treatment approaches available for early stage prostate cancer offered at UCLA. It offers the appropriate candidate a minimally invasive treatment with less blood loss and a more rapid overall recovery. On the following pages, we describe this procedure in greater detail, provide information on who are appropriate candidates, help sort out the proven advantages of this approach from those that are merely claimed, and describe its place in the overall treatment armemantarium offered to patients with early stage prostate cancer. "

The Robotically-assisted laparoscopic prostatectomy is performed by Robert Reiter, MD and Peter Schulam, MD, Department of Urology at UCLA.




*Prostate Cancer Treatments at UCLA* "Prostate cancer is the most common cancer diagnosis in American men, with approximately 220,000 new cases expected in the United States this year. Advances in screening combined with aggressive treatment have led to a 25% decrease in prostate cancer related death, with a decline from more than 40,000 deaths in the early 1990s to ~30,000 deaths in 2004. UCLA Urology's Prostate Cancer Program is recognized internationally as one of the premier prostate programs in the world both for its cutting edge research and clinical programs. UCLA is one of only 11 centers nationwide recognized as a Center of Excellence in prostate cancer and is funded by an $11 million "SPORE" grant from the National Cancer Institute for prostate cancer research. UCLA's Prostate Cancer Program is committed to providing the full spectrum of cancer care for its patients, based on the belief that no single treatment is right for every individual. For early stage prostate cancer, we offer nerve-sparing radical prostatectomy, robotically assisted laparoscopic prostatectomy, permanent and temporary brachytherapy, cryotherapy and external beam radiotherapy (IMRT). Uniquely, patient care at UCLA is integrated closely with our research mission in order to advance the state of the art. Examples of this include the integration of quality of life assessments with treatment for early stage disease and the availability of clinical trials stemming from UCLA research and beyond for men with locally advanced and metastatic cancers. Robotically-assisted laparoscopic prostatectomy is one of the newest treatment approaches available for early stage prostate cancer offered at UCLA. It offers the appropriate candidate a minimally invasive treatment with less blood loss and a more rapid overall recovery. On the following pages, we describe this procedure in greater detail, provide information on who are appropriate candidates, help sort out the proven advantages of this approach from those that are merely claimed, and describe its place in the overall treatment armemantarium offered to patients with early stage prostate cancer. " The Robotically-assisted laparoscopic prostatectomy is performed by Robert Reiter, MD and Peter Schulam, MD, Department of Urology at UCLA. [RECOVERY] [LAPAROSCOPIC VS OPEN PROSTATECTOMY] [VIDEOS] [UCLA UROLOGY] [OTHER PROSTATE CANCER TREATMENTS AT UCLA] [DI VINCI ROBOT WEBSITE] ©2005, UCLA Department of Urology. All rights reserved.						The di Vinci Robot by Intuitive Surgical UCLA SPORE in Prostate Cancer Clinical Trials in Prostate Cancer